Integer Holdings Corporation (ITGR) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $91.30, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (53.0%); Concentration risk — Supplier: single supplier raw materials.
Integer Holdings Corporation is a CDMO serving Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets for large OEM medical device manufacturers globally. Revenue comes from contract manufacturing under supply agreements; Abbott Laboratories, Boston... Read more
Hold if already holding. Not a fresh buy at $91.30, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (53.0%); Concentration risk — Supplier: single supplier raw materials. Chart setup: RSI 59 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 44d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Integer Holdings Corporation
About Integer Holdings Corporation
Integer Holdings Corporation held $675 million in firm backlog at December 31, 2025, with Abbott Laboratories, Boston Scientific, and Medtronic each exceeding 10% of 2025 total sales and together representing 49% of revenues. A pure-play CDMO across Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, Integer manufactures in seven countries and held 731 patents at year-end.
Integer earns revenue through long-term supply agreements with large OEM medical device manufacturers, producing components, subassemblies, and finished devices for procedures spanning interventional cardiology, structural heart, electrophysiology, neuromodulation, and spinal cord stimulation, among others. Contracts typically specify minimum order quantities but not always minimum purchase levels, meaning OEM inventory management decisions—including vertical integration or alternate supply arrangements—can produce material revenue variability. The company's raw material base includes platinum, titanium, nitinol, lithium, and iridium, some obtained from a single supplier; disruptions or price increases not recoverable through customer pricing could weigh on margins. During 2025, Integer completed three tuck-in acquisitions—Biocoat Incorporated (December), VSi Parylene (February), and Precision Coating LLC (January)—adding UV-cure hydrophilic, parylene, and fluoropolymer coating platforms.
Show full overview
Integer's primary operating risk is customer concentration: supply agreements with its largest OEM partners may lack minimum purchase commitments, and the 10-K notes that reductions in customer demand have negatively impacted results in prior fiscal years and may recur if significant customers reduce orders. Those partners may also have vertical integration or alternate supply plans they do not share with Integer. In March 2026, Integer disclosed via Form 8-K a Cooperation Agreement with activist investor Irenic Capital Management, appointing two new board members and initiating a strategic review that could affect the company's operating strategy.
See also: Healthcare · Medical Devices
From Integer Holdings Corporation's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — Integer Holdings Corporation
Latest news
- NEWS Here's why you should retain Integer Holdings stock in your portfolio - MSN — MSN positive
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - Yahoo Finance — Yahoo Finance neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - StockStory — StockStory neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - MSN — MSN neutral
- NEWS What To Expect From Integer Holdings’s (ITGR) Q1 Earnings - FinancialContent — FinancialContent neutral
Generated 2026-06-17T10:31:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerAbbott Laboratories, Boston Scientific and Medtronic49%10-K Item 1: 'three of our customers, Abbott Laboratories, Boston Scientific and Medtronic were each in excess of 10% of total sales and collectively accounted for 49% of our total sales.'
- HIGHGeographicUnited States53%10-K Item 1: 'approximately 53% of our products sold were shipped to locations in the United States'
- HIGHSuppliersingle supplier raw materials10-K Item 1A: 'we obtain some raw materials from a single supplier'
Material Events(8-K, last 90d)
- 2026-05-22Item 5.02LOWOn May 18, 2026 the Compensation Committee approved amendments to CEO Payman Khales' employment agreement providing enhanced change-of-control vesting for performance equity awards, in connection with a previously announced strategic review. No officer departure.SEC filing →
- 2026-03-12Item 1.01MEDIUMInteger entered a Cooperation Agreement with Irenic Capital Management LP on March 9, 2026, appointing James F. Flanagan and Aaron Kapito to the Board; two unnamed incumbent directors agreed not to stand for re-election at the 2026 Annual Meeting.SEC filing →
- 2026-03-12Item 5.02LOWJames F. Flanagan (Company Director) and Aaron Kapito (Investor Designated Director per Irenic Capital) appointed to the Board on March 9, 2026 per Cooperation Agreement; two unnamed incumbent directors to step down at 2026 Annual Meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $91.30, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (53.0%); Concentration risk — Supplier: single supplier raw materials. Chart setup: RSI 59 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $92.86 (+1.7%), stop $86.66 (−5.4%), A.R:R -1.4:1. Score 4.6/10, moderate confidence.
Take-profit target: $92.86 (+1.7% upside). Target $92.86 (+1.7%), stop $86.66 (−5.4%), A.R:R -1.4:1. Stop-loss: $86.66.
Concentration risk — Geographic: United States (53.0%); Concentration risk — Supplier: single supplier raw materials; Analyst target reached - limited upside remaining.
Integer Holdings Corporation trades at a P/E of 22.5 (forward 13.3). TrendMatrix value score: 5.9/10. Verdict: Hold.
17 analysts cover ITGR with a consensus score of 3.8/5. Average price target: $98.
What does Integer Holdings Corporation do?Integer Holdings Corporation is a CDMO serving Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and...
Integer Holdings Corporation is a CDMO serving Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets for large OEM medical device manufacturers globally. Revenue comes from contract manufacturing under supply agreements; Abbott Laboratories, Boston Scientific, and Medtronic collectively represented 49% of 2025 sales, with firm backlog of approximately $675 million at December 31, 2025.